Base Editing Market Size, Share & Trends

Updated on : September 24, 2024

Overview of the Base Editing Market

The global Base editing market, valued at US$260 million in 2022, is forecasted to grow at a robust CAGR of 15.2%, reaching US$270 million in 2023 and an impressive US$549 million by 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the base editing market is largely driven by the rising prevalence of genetic diseases, and the increasing recognition of the role of genetic mutations in various diseases has fueled the demand for precise gene editing technologies.

Base Editing Market - Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Base Editing Market

Global Base Editing Market Dynamics

Driver: Rising prevalence of rare diseases

As the prevalence of rare and orphan diseases continues to rise, there is a growing demand for innovative therapies to address them. This surge in demand has put gene editing technologies at the forefront of rare disease research and treatment. Since rare diseases often stem from genetic mutations, approaches like base editing are now playing a pivotal role in the quest for effective treatments. This increase in the prevalence of rare diseases is expected to drive substantial growth in the base editing market in the coming years, as researchers and medical professionals work to develop novel therapies for these challenging conditions.

Restraint: Ethical & safety concerns

The application of gene editing, even when carried out with noble intentions, carries inherent risks of unforeseen consequences. Alterations made to a single gene can inadvertently influence the regulation of other genes, potentially resulting in unanticipated and long-term effects. The introduction of base editing technology has given rise to legitimate ethical and safety concerns, which serve as significant barriers to its widespread adoption in the market. While base editing is generally recognized for its increased precision compared to traditional CRISPR-Cas9 methods, it is not entirely immune to the possibility of off-target effects. The inadvertent modifications to DNA can give rise to detrimental outcomes, necessitating a vigilant focus on enhancing the safety and specificity of base editing techniques to minimize these risks. As technology continues to advance, it is imperative to engage in transparent and inclusive dialogues aimed at addressing these concerns. This entails weighing the potential benefits against the associated risks and steadfastly upholding ethical and safety principles to navigate the complex landscape of gene editing.

Opportunity: Increasing pipeline of gene therapy & regulatory approvals

The expanding pipeline for gene therapy in the base editing market presents significant opportunities for advancements in the treatment of genetic disorders and other diseases. Gene therapy involves the delivery of therapeutic genes or gene editing tools into the patient's cells to correct genetic mutations, restore normal gene function, or introduce therapeutic genes for targeted treatment. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases. The base editing market is expected to benefit from the growing number of gene therapy products in the pipeline. There are over 1,000 gene therapy products in development, with over 200 of these products in clinical trials. Most of these products are targeting cancer, but there are also several products targeting genetic disorders, such as haemophilia and cystic fibrosis. For instance, in 2022, the FDA approved the first gene therapy product for the treatment of cancer.

Challenge: Challenges associated with off-target effects

The primary concern with off-target effects is the unintentional modification of DNA sequences at locations other than the intended target. Even minimal off-target changes can lead to undesirable and potentially harmful consequences, such as introducing new mutations or disrupting the function of other genes. While base editors are designed to recognize a specific DNA sequence, they may still bind to similar sequences in the genome, resulting in off-target effects. Developing base editors with enhanced specificity is an ongoing challenge. Researchers are continually working to improve the design and engineering of base editors to reduce the risk of off-target effects. This includes refining the binding domains and the catalytic mechanisms to increase precision.

Global Base Editing Market Ecosystem Analysis

The ecosystem of base editing consists of end users from pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations base editing product and service providers, reagent & kits suppliers, technology providers, data management & analysis providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of base editing products and services, enhance drug discovery processes, and develop new therapeutics.

Platform held a dominant share in the product & service segment in the base editing industry.

By product and service, the base editing market has been further categorized as product and services. Service segment is further categorized as gRNA design, cell line engineering, and other services. The product segment is further categorized as platform, kits & reagents, plasmids, and base editing libraries. In 2022, platform accounted for the largest share of the base editing market. Base editing platforms are integral for therapeutic genome editing applications, where precision and efficiency are critical. Pharmaceutical and biotechnology companies developing gene therapies prefer comprehensive base editing platforms to ensure accurate and reliable results in therapeutic interventions.

The Cytosine base editor segment is expected to register the fastest growth in the base editing industry during the forecast period.

Based on the targeted base the base editing market has been segmented into cytosine base editor and adenine base editor. In 2022, cytosine base editor accounted for the largest share. This can be attributed to the fact that cytosine base editing allows researchers to model disease-causing mutations more easily by introducing specific changes associated with certain genetic disorders. Technological advancements in the field of proteomics and genomics are expected to support the growth of this segment.

North America accounted for the largest share in Base editing industry in 2022.

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the Base editing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the dominant share followed by Europe. North America has a well-established infrastructure for funding research and development initiatives, providing financial support to companies working on base editing technologies. Moreover, the regulatory environment in North America is often supportive of innovation in the life sciences sector.

Key players in the global Base editing market include Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), EdiGene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI-Biodesignhttps://www.qi-biodesign.com/ (China), KromaTiD, Inc. (US), and GenKOre. (South Korea).

Scope of the Base Editing Industry

This report categorizes the base editing market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Product
  • Platform
  • Kits & Reagents
  • Plasmids
  • Base Editing Libraries
• Services
  • gRNA Design
  • Cell line engineering
  • Other Services

By Type

• DNA base editing
• RNA base editing

By Targeted base

• Cytosine base editing
• Adenine base editing

By Application

• Drug Discovery & Development
• Agriculture
• Veterinary

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • RoLATAM
• Middle East & Africa
  • Middle East
  • Africa

Recent Developments of Base Editing Industry

• In May 2023, Revvity entered into a license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.
• In July 2022, Beam Therapeutics entered a collaboration with Verve Therapeutics. Beam Tx granted Verve Tx a license toward an additional liver-mediated cardiovascular disease target.
• In February 2022, Intellia Therapeutics acquired Rewrite Therapeutics; a private biotechnology company focused on advancing novel DNA writing technologies. This acquisition has expanded Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologies.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst